Connect with us

Hi, what are you looking for?

News

Zymeworks’ Robust Financials And The Potential Biotech Resurgence (NASDAQ:ZYME)

Introduction

Zymeworks (NASDAQ:ZYME) is a biotech firm dedicated to crafting novel, multifunctional biotherapeutics, especially for challenging cancers and diseases. Their primary product, zanidatamab, is a bispecific antibody targeting HER2. Collaborations exist with BeiGene (BGNEJAZZ

Read the full article here

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Videos

Watch full video on YouTube

News

This article was written by Follow The Value Portfolio specializes in building retirement portfolios and utilizes a fact-based research strategy to identify investments. This...

Videos

Watch full video on YouTube

Videos

Watch full video on YouTube